The skin gateway
to the Immune System

Scientific Publications

Filtred by year :

  • Mar, 05 2012
  • Dioszeghy Vincent, Mondoulet Lucie

American Academy of Allergy, Asthma and Immunology


Abstract - Protection from Oral Peanut-Induced Esophageal Lesions in Sensitized Mice treated by Epicutaneous Immunotherapy is Mediated by CD25+CD4+Tregs


Read this abstract (181.3 KB)


  • Mar, 05 2012
  • Mondoulet Lucie, Dioszeghy Vincent

American Academy of Allergy, Asthma and Immunology


Abstract - In Mice Sensitized to Milk, Epicutaneous Immunotherapy Prevents Further Sensitization to Peanut or House Dust Mite


Read this abstract (181.5 KB)


  • Feb, 05 2012
  • Mondoulet Lucie, Dioszeghy Vincent

PLoS ONE


Epicutaneous Immunotherapy (EPIT) Blocks the Allergic Esophago-Gastro-Enteropathy Induced by Sustained Oral Exposure to Peanuts in Sensitized Mice


Read this article (3.2 MB)


  • Jan, 04 2012
  • Mondoulet Lucie, Dioszeghy Vincent

ISRN Allergy


Epicutaneous Immunotherapy Compared with Sublingual Immunotherapy in Mice Sensitized to Pollen (Phleum pratense)


Read this article (1001.6 KB)


DBV Technologies has a strong intellectual property portfolio with patents covering both the technology platform (VIASKIN® technology) and the EPIT desensitisation method.

Products


DBV has developed a unique range of allergy diagnosis and treatment products

Legal Mention

CNIL number: 1544201 v 0

DBV technologies - siège social
Green Square - Bâtiment D
80/84 rue des Meuniers
92220 Bagneux
France
Phone: +33 (0)1 55 42 78 78
Fax: +33 (0)1 43 26 10 83

SIRET: 441772522 00013
RCS: Nanterre

Executive editor: Pierre-Henri Benhamou

Hosting service: OVH www.ovh.com

Design : l’enchanteur www.lenchanteur.com

Contact